Cargando…

Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets

Ovarian cancer remains the most fatal gynecologic malignancy worldwide due to delayed diagnosis as well as recurrence and drug resistance. Thus, the development of new tumor-related molecules with high sensitivity and specificity to replace or supplement existing tools is urgently needed. Cancer-tes...

Descripción completa

Detalles Bibliográficos
Autores principales: Xie, Kaipeng, Fu, Chenyang, Wang, Suli, Xu, Hanzi, Liu, Siyu, Shao, Yang, Gong, Zhen, Wu, Xiaoli, Xu, Bo, Han, Jing, Xu, Juan, Xu, Pengfei, Jia, Xuemei, Wu, Jiangping
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BioMed Central 2019
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318940/
https://www.ncbi.nlm.nih.gov/pubmed/30609934
http://dx.doi.org/10.1186/s13048-018-0475-z
_version_ 1783384976491806720
author Xie, Kaipeng
Fu, Chenyang
Wang, Suli
Xu, Hanzi
Liu, Siyu
Shao, Yang
Gong, Zhen
Wu, Xiaoli
Xu, Bo
Han, Jing
Xu, Juan
Xu, Pengfei
Jia, Xuemei
Wu, Jiangping
author_facet Xie, Kaipeng
Fu, Chenyang
Wang, Suli
Xu, Hanzi
Liu, Siyu
Shao, Yang
Gong, Zhen
Wu, Xiaoli
Xu, Bo
Han, Jing
Xu, Juan
Xu, Pengfei
Jia, Xuemei
Wu, Jiangping
author_sort Xie, Kaipeng
collection PubMed
description Ovarian cancer remains the most fatal gynecologic malignancy worldwide due to delayed diagnosis as well as recurrence and drug resistance. Thus, the development of new tumor-related molecules with high sensitivity and specificity to replace or supplement existing tools is urgently needed. Cancer-testis antigens (CTAs) are exclusively expressed in normal testis tissues but abundantly found in several types of cancers, including ovarian cancer. Numerous novel CTAs have been identified by high-throughput sequencing techniques, and some aberrantly expressed CTAs are associated with ovarian cancer initiation, clinical outcomes and chemotherapy resistance. More importantly, CTAs are immunogenic and may be novel targets for antigen-specific immunotherapy in ovarian cancer. In this review, we attempt to characterize the expression of candidate CTAs in ovarian cancer and their clinical significance as biomarkers, activation mechanisms, function in malignant phenotypes and applications in immunotherapy.
format Online
Article
Text
id pubmed-6318940
institution National Center for Biotechnology Information
language English
publishDate 2019
publisher BioMed Central
record_format MEDLINE/PubMed
spelling pubmed-63189402019-01-08 Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets Xie, Kaipeng Fu, Chenyang Wang, Suli Xu, Hanzi Liu, Siyu Shao, Yang Gong, Zhen Wu, Xiaoli Xu, Bo Han, Jing Xu, Juan Xu, Pengfei Jia, Xuemei Wu, Jiangping J Ovarian Res Review Ovarian cancer remains the most fatal gynecologic malignancy worldwide due to delayed diagnosis as well as recurrence and drug resistance. Thus, the development of new tumor-related molecules with high sensitivity and specificity to replace or supplement existing tools is urgently needed. Cancer-testis antigens (CTAs) are exclusively expressed in normal testis tissues but abundantly found in several types of cancers, including ovarian cancer. Numerous novel CTAs have been identified by high-throughput sequencing techniques, and some aberrantly expressed CTAs are associated with ovarian cancer initiation, clinical outcomes and chemotherapy resistance. More importantly, CTAs are immunogenic and may be novel targets for antigen-specific immunotherapy in ovarian cancer. In this review, we attempt to characterize the expression of candidate CTAs in ovarian cancer and their clinical significance as biomarkers, activation mechanisms, function in malignant phenotypes and applications in immunotherapy. BioMed Central 2019-01-04 /pmc/articles/PMC6318940/ /pubmed/30609934 http://dx.doi.org/10.1186/s13048-018-0475-z Text en © The Author(s). 2019 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated.
spellingShingle Review
Xie, Kaipeng
Fu, Chenyang
Wang, Suli
Xu, Hanzi
Liu, Siyu
Shao, Yang
Gong, Zhen
Wu, Xiaoli
Xu, Bo
Han, Jing
Xu, Juan
Xu, Pengfei
Jia, Xuemei
Wu, Jiangping
Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets
title Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets
title_full Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets
title_fullStr Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets
title_full_unstemmed Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets
title_short Cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets
title_sort cancer-testis antigens in ovarian cancer: implication for biomarkers and therapeutic targets
topic Review
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6318940/
https://www.ncbi.nlm.nih.gov/pubmed/30609934
http://dx.doi.org/10.1186/s13048-018-0475-z
work_keys_str_mv AT xiekaipeng cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets
AT fuchenyang cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets
AT wangsuli cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets
AT xuhanzi cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets
AT liusiyu cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets
AT shaoyang cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets
AT gongzhen cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets
AT wuxiaoli cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets
AT xubo cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets
AT hanjing cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets
AT xujuan cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets
AT xupengfei cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets
AT jiaxuemei cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets
AT wujiangping cancertestisantigensinovariancancerimplicationforbiomarkersandtherapeutictargets